Foghorn Therapeutics

Forecast & Rating11 analysts currently cover Foghorn Therapeutics, with about 45.5% giving a positive rating — meaning they expect the stock to rise. The average price target is $4.17, about 125.2% upside from the current price of $1.85. Price targets range from $2.00 to $5.00 — a wide spread, showing clear disagreement over just how much Foghorn Therapeutics can rise. Historically, about 1.5% of past price targets were eventually met, which adds credibility. For you, this means institutional views on Foghorn Therapeutics are split — bulls and bears coexist, so you'll need to weigh it against your own judgment. Data as of Oct 13, 2026; for reference only and not investment advice.